MetALD: Genetic Factors and Clinical Outcomes
Seminars in Liver Disease · 01.09.2025 · 45 (03) · 269-282
DOI: 10.1055/a-2630-0952 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, erschienen am 01.09.2025. Verfasst von Mads Israelsen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Centre for Liver Research, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Fatty Liver, Liver Diseases, Alcoholic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 107 Literaturangaben.
Abstract (Originalsprache)
Metabolic and alcohol-related liver disease (MetALD) is a subcategory of steatotic liver disease (SLD) characterized by the coexistence of cardiometabolic risk factors and elevated alcohol intake. The global prevalence of MetALD is estimated to be 2 to 5%, but this is likely underestimated due to self-reporting biases. In real-world settings, fluctuations in alcohol intake mean that many patients with SLD may be classified as having MetALD at some point during their disease. Although MetALD is relatively common, only a minority of patients with the disorder progress to advanced chronic liver disease. Genetic factors modulate disease initiation and progression, with risk variants in PNPLA3, HSD17B13, and TM6SF2 being particularly relevant. Polygenic risk scores incorporating these and other variants have demonstrated a potential for identifying at-risk individuals. This review comprehensively examines MetALD, covering its natural history, genetic underpinnings, clinical outcomes, the predictive potential of genetic risk scores, and future therapeutic avenues involving gene silencing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Centre for Liver Research, Odense University Hospital, Odense, Denmark.
- Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.
- Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
- Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Brussels, Belgium.
- Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Zitieren
APA
Israelsen, M., Trépo, E., Krag, A., & Stender, S. (2025). MetALD: Genetic Factors and Clinical Outcomes. Seminars in Liver Disease, 45(03), 269-282. https://doi.org/10.1055/a-2630-0952
Vancouver
Israelsen M, Trépo E, Krag A, Stender S. MetALD: Genetic Factors and Clinical Outcomes. Seminars in Liver Disease. 2025;45(03):269-282. doi:10.1055/a-2630-0952
BibTeX
@article{Israelsen2025,
author = {Israelsen, Mads and Trépo, Eric and Krag, Aleksander and Stender, Stefan},
title = {MetALD: Genetic Factors and Clinical Outcomes},
journal = {Seminars in Liver Disease},
year = {2025},
volume = {45},
number = {03},
pages = {269--282},
doi = {10.1055/a-2630-0952}
}
EUVIMED